Company news
Karyopharm Therapeutics Inc. news in 2019
Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2019, newest first.
Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 22, 2019
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting
December 6, 2019
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
November 5, 2019
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
November 3, 2019
Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019
October 27, 2019
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
September 15, 2019
Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop
September 12, 2019
Decks in 2019
- ASCO GU 2019
Conference · 10 slides · May 2019
- JP Morgan Healthcare Conference 2019
Conference · 34 slides · Jan 7, 2019